Fulminant B hepatitis in a surface antigen-negative patient with B-cell chronic lymphocytic leukaemia after rituximab therapy
✍ Scribed by Niscola, P; Del Principe, M I; Maurillo, L; Venditti, A; Buccisano, F; Piccioni, D; Amadori, S; Del Poeta, G
- Book ID
- 110056434
- Publisher
- Nature Publishing Group
- Year
- 2005
- Tongue
- English
- Weight
- 74 KB
- Volume
- 19
- Category
- Article
- ISSN
- 0887-6924
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
Fludarabine is used widely for the treatment of chronic lymphocytic leukaemia, but not as yet implicated in the emergence of hepatitis B surface antigen (HBsAg) variants following hepatitis B virus (HBV) reactivation. Such a variant was detected in a 78-year-old female who was HBsAg(-)/anti-HBc(+)/a
## Abstract Hepatitis B and hepatitis D viral genomes were tested by nested polymerase chain reaction in the serum and liver of 69 hepatitis B surface antigen (HBsAg) negative, anti‐hepatitis C virus (HCV) positive patients (47 with HCV RNA and 22 without HCV RNA). Serum hepatitis B virus (HBV) DNA